A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
This study is ongoing, but not recruiting participants.
Sponsor:
Vaxil Therapeutics Ltd.
Information provided by (Responsible Party):
Vaxil Therapeutics Ltd.
ClinicalTrials.gov Identifier:
NCT01232712
First received: October 22, 2010
Last updated: August 29, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The scientific approach behind this study is to develop novel anti-cancer therapeutic vaccine to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes populations and can be be applicable to the majority of the target population.
| Condition | Intervention | Phase |
|---|---|---|
|
Multiple Myeloma |
Biological: ImMucin, hGM-CSF |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies |
Resource links provided by NLM:
Further study details as provided by Vaxil Therapeutics Ltd.:
Primary Outcome Measures:
- Safety of intradermal or subcutaneous administration of the ImMucin peptide [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Determine the safety and initial feasibility of intradermal or subcutaneous administration of the ImMucin peptide combined with hGM-CSF for maximal stimulation of T cell response.
The patients will receive six or twelve biweekly injections of Imucin (3 or 6 months). Post Treatment visit will be performed 4 weeks after administration of last vaccination. FU telephone calls will be made up to 6 months following the last vaccination in order to assess the status of the disease.
Secondary Outcome Measures:
- Assess efficacy of study treatment [ Time Frame: 6 months ] [ Designated as safety issue: No ]Assessment of respose to treatment during treatment period (3 or 6 months).Post Treatment visit will be performed 4 weeks after administration of last vaccination. FU telephone calls will be made up to 6 months following the last vaccination in order to assess the status of the disease.
| Estimated Enrollment: | 15 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | February 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: ImMucin
Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
|
Biological: ImMucin, hGM-CSF
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- All* patients must have a histological or cytological diagnosis of metastatic disease or hematological malignancies expressing the MUC1. Patients must have metastatic disease, and have failed at least one regimen of standard based chemotherapy for metastatic disease as indicated in the following table. Patients must have disease considered to be incurable by surgical or radiological intervention.
- Patients must be > 18 years of age, consenting to participate in the study.
- Patients must have at least one site of measurable tumor or measurable tumor marker.
- Radiological and other relevant imaging studies, such as CT scans, must be performed within 4 weeks of the first treatment as a baseline to document extent of disease.
- Patients should be at least 4 weeks beyond any major surgery or chemoradiotherapy and have recovered from drug induced toxicity.
- Patients must have a performance status of 70% or greater on the Karnofsky scale (ECOG 0-2) and a minimal life expectancy of 12 months.
Patients must sign an informed consent, and be mentally responsible.
- In Multiple Myeloma, MUC1 expression will be tested after confirming that all inclusion/exclusion criteria are met and within the screening period.
Exclusion Criteria:
- Patients not fulfilling the above criteria.
- Patients with a significant concurrent medical complication that in the judgment of the Principal Investigator could affect the patient's ability to tolerate or complete this study.
- Patients receiving any immunosuppressive treatment that could negate development of an effective immune response to the vaccine. (First vaccination should be at least 30 days from end of immunosuppressive treatment)
- Subjects with prior irradiation to a field that includes more than 25% of their lymph nodes and bone marrow likely to be immunosuppressed will be excluded. However, patients who had standard pelvic field radiation as adjuvant therapy for rectal cancer are not excluded.
- Pregnant and breast feeding women will be excluded. Premenopausal women who are not practicing or willing to practice adequate birth control methods for a period of 3 months after treatment will be excluded.
- Patients with brain metastasis.
- Patients with active infection.
- Patients with HIV HBSAg and HCV positive.
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Vaxil Therapeutics Ltd. |
| ClinicalTrials.gov Identifier: | NCT01232712 History of Changes |
| Other Study ID Numbers: | VAXIL-001 |
| Study First Received: | October 22, 2010 |
| Last Updated: | August 29, 2012 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Vaxil Therapeutics Ltd.:
|
MUC1 ImMucin Vaccine Multiple Myeloma |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013